CLINICAL TRIALS PROFILE FOR XCOPRI
✉ Email this page to a colleague
All Clinical Trials for XCOPRI
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT04903314 ↗ | Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures | Recruiting | SK Life Science, Inc. | Phase 1 | 2021-05-27 | The primary objective of this study is to assess the pharmacokinetics of cenobamate (YKP3089) in pediatric subjects with partial-onset (focal) seizures following single and multiple-dosing. |
NCT05067634 ↗ | Safety and Efficacy Extension Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures | Not yet recruiting | SK Life Science, Inc. | Phase 3 | 2021-11-01 | Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for XCOPRI
Condition Name
Clinical Trial Locations for XCOPRI
Trials by Country
Clinical Trial Progress for XCOPRI
Clinical Trial Phase
Clinical Trial Sponsors for XCOPRI
Sponsor Name